WO2003082187A3 - Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique - Google Patents

Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique Download PDF

Info

Publication number
WO2003082187A3
WO2003082187A3 PCT/US2003/007563 US0307563W WO03082187A3 WO 2003082187 A3 WO2003082187 A3 WO 2003082187A3 US 0307563 W US0307563 W US 0307563W WO 03082187 A3 WO03082187 A3 WO 03082187A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmnat
modifying
composition
adenylyltranserase
nmn
Prior art date
Application number
PCT/US2003/007563
Other languages
English (en)
Other versions
WO2003082187A2 (fr
Inventor
Hiremagalur N Jayaram
Joel A Yalowitz
Original Assignee
Indiana University
Hiremagalur N Jayaram
Joel A Yalowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University, Hiremagalur N Jayaram, Joel A Yalowitz filed Critical Indiana University
Priority to AU2003220201A priority Critical patent/AU2003220201A1/en
Publication of WO2003082187A2 publication Critical patent/WO2003082187A2/fr
Publication of WO2003082187A3 publication Critical patent/WO2003082187A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition conçue pour modifier la production de NAD. Cette composition comprend un composant qui modifie les NMNAT ainsi qu'un excipient pharmaceutiquement acceptable. L'invention se rapporte également à une séquence d'ADN complémentaire codant les NMNAT. L'invention concerne par ailleurs un procédé permettant de traiter par exemple un diabète, un cancer, un infarctus du myocarde, un accident vasculaire cérébral, des troubles neurodégénératifs, un choc, et le vieillissement, par administration à un patient d'une dose efficace d'une composition conçue pour modifier la production de NAD. L'invention se rapporte en outre à une thérapie génique faisant appel à une séquence codant les NMNAT et un procédé permettant d'introduire cette séquence efficacement dans le génome d'un hôte.
PCT/US2003/007563 2002-03-26 2003-03-13 Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique WO2003082187A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003220201A AU2003220201A1 (en) 2002-03-26 2003-03-13 Purification and cloning of nmn adenylyltranserase and its therapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36807802P 2002-03-26 2002-03-26
US60/368,078 2002-03-26

Publications (2)

Publication Number Publication Date
WO2003082187A2 WO2003082187A2 (fr) 2003-10-09
WO2003082187A3 true WO2003082187A3 (fr) 2003-12-04

Family

ID=28675440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007563 WO2003082187A2 (fr) 2002-03-26 2003-03-13 Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique

Country Status (2)

Country Link
AU (1) AU2003220201A1 (fr)
WO (1) WO2003082187A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259782A4 (fr) 2008-03-03 2013-01-23 Nad Life Pty Ltd Formulations pharmaceutiques de resvératrol et procédés d'utilisation de celles-ci pour traiter des troubles cellulaires
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
EP2584041A1 (fr) * 2011-10-21 2013-04-24 Industrial Cooperation Foundation Chonbuk National University Composition pour prévenir ou traiter le diabète comprenant un inhibiteur nad glycohydrolase comme ingrédient actif
JP6820653B2 (ja) * 2011-12-14 2021-01-27 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的
WO2013130672A2 (fr) * 2012-02-27 2013-09-06 United States Of America As Represented By The Department Of Veterans Affairs Traitements et diagnostics améliorés du cancer
CN104487575B (zh) * 2012-07-28 2017-09-19 深圳华大基因股份有限公司 Nmnat1突变基因、检测其的引物、试剂盒和方法以及其用途
CN103710321B (zh) * 2013-12-31 2015-04-01 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸腺苷转移酶突变体及其编码基因和应用
CN107475139A (zh) * 2017-09-30 2017-12-15 广州大学 一种pH稳定型发酵培养基及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALDUCCI ET AL.: "Assay methods for nicotinamide mononucleotide adenyltransferase of wide applicability", ANALYTICAL BIOCHEMISTRY, vol. 228, 1995, pages 64 - 68, XP002970567 *
RAFFAELLI ET AL.: "Identification of a novel human nicotinamide mononucleotide adenyltransferase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, vol. 297, 2002, pages 835 - 840, XP002243554 *
ROSENBERG ET AL.: "Gene therapist, heal thyself", SCIENCE, vol. 287, March 2000 (2000-03-01), pages 1751, XP002954000 *
WOOD ET AL.: "The genome of the natural genetic engineer agrobacterium tumefaciens C58", SCIENCE, vol. 294, December 2001 (2001-12-01), pages 2317 - 2323, XP002226726 *

Also Published As

Publication number Publication date
AU2003220201A8 (en) 2003-10-13
WO2003082187A2 (fr) 2003-10-09
AU2003220201A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
WO2003032994A3 (fr) Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
WO2002066477A3 (fr) Composes
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
TNSN07048A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
PL1928499T3 (pl) Zastosowanie inhibitora DPP-IV do ograniczania epizodów hipoglikemii
IN2015DN01132A (fr)
WO2004037181A3 (fr) Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
WO2002065979A3 (fr) Nouveaux composes de pyrimidine
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
AU2003282215A1 (en) Anti-cancer composition comprising dmxaa or related compound
WO2009025760A3 (fr) Compositions de phénylalanine ammoniac/lyase procaryotiques et des procédés de traitement du cancer en utilisant des compositions de celles-ci
EP1933833B8 (fr) Therapie pour le traitement de la vessie hyperactive
WO2003002593A3 (fr) Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
WO2005033099A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
GB2405147A (en) Therapeutic molecules and methods-1
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
IL175014A0 (en) Method of administering therapeutic injections
WO2006026204A3 (fr) Nouvelles gamma-lactames servant d'inhibiteurs de beta-secretase
WO2003082187A3 (fr) Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP